Table 4.
Summary of hippocampal protein and amyloid levels by diagnosis category
| Clinical Diagnosis | ||||||
|---|---|---|---|---|---|---|
| NCI (n=10) | MCI (n=15)* | AD (n=14)* | Total (n=39) | P value a | ||
| rabaptin5: | Mean ± SD (Range) | 0.072 ± 0.029 (0.034–0.11) | 0.097 ± 0.019 (0.072–0.14) | 0.069 ± 0.026 (0.035–0.12) | 0.081 ± 0.027 (0.034–0.14) | 0.033 b |
| Cat D: | Mean ± SD (Range) | 0.071 ± 0.031 (0.034–0.13) | 0.093 ± 0.030 (0.053–0.14) | 0.058 ± 0.022 (0.032–0.097) | 0.076 ± 0.031 (0.032–0.14) | 0.021 b |
| rab5: | Mean ± SD (Range) | 0.049 ± 0.012 (0.036–0.077) | 0.052 ± 0.018 (0.024–0.081) | 0.050 ± 0.012 (0.033–0.073) | 0.050 ± 0.014 (0.024–0.081) | 0.9 |
| pmTORs2448: | Mean ± SD (Range) | 0.45 ± 0.09 (0.34–0.63) | 0.40 ± 0.16 (0.23–0.76) | 0.51 ± 0.32 (0.13–1.19) | 0.45 ± 0.22 (0.13–1.19) | 0.3 |
| pmTORs2481: | Mean ± SD (Range) | 0.50 ± 0.16 (0.33–0.80) | 0.50 ± 0.16 (0.30–0.73) | 0.61 ± 0.19 (0.29–0.97) | 0.54 ± 0.17 (0.29–0.97) | 0.2 |
| mTOR: | Mean ± SD (Range) | 0.35 ± 0.07 (0.23–0.46) | 0.32 ± 0.09 (0.22–0.53) | 0.40 ± 0.14 (0.18–0.66) | 0.36 ± 0.11 (0.18–0.66) | 0.2 |
| p62: | Mean ± SD (Range) | 0.16 ± 0.05 (0.11–0.25) | 0.19 ± 0.11 (0.08–0.38) | 0.14 ± 0.10 (0.07–0.44) | 0.17 ± 0.09 (0.07–0.44) | 0.3 |
| traf6: | Mean ± SD (Range) | 0.21 ± 0.08 (0.13–0.42) | 0.21 ± 0.06 (0.14–0.35) | 0.22 ± 0.06 (0.12–0.31) | 0.22 ± 0.06 (0.12–0.42) | 0.8 |
| LilrB2: | Mean ± SD (Range) | 0.19 ± 0.10 (0.08–0.36) | 0.19 ± 0.09 (0.08–0.34) | 0.27 ± 0.18 (0.10–0.65) | 0.22 ± 0.14 (0.08–0.65) | 0.4 |
| Total Aβ40*: | Mean ± SD (Range) | 0.99 ± 0.81 (0.08–2.31) | 1.57 ± 2.03 (0.08–5.97) | 1.46 ± 1.40 (0.14–5.30) | 1.38 ± 1.53 (0.08–5.97) | 0.6 |
| Total Aβ42*: | Mean ± SD (Range) | 3.33 ± 2.45 (0.92–7.14) | 4.32 ± 2.39 (1.03–7.68) | 4.72 ± 1.62 (1.95–7.15) | 4.21 ± 2.17 (0.92–7.68) | 0.2 |
a
Kruskal-Wallis test, with Bonferroni-type correction for pairwise comparisons.
b
MCI > AD.
*
- 1 MCI patient did not have rabaptin5, Cat D, Rab5, Aβ40, or Aβ42 available.
- 2 MCI patients did not have traf6, LilrB2, pmTORs2448, pmTORs2481, mTOR or p62 available.
- 3 AD patients did not have rabaptin5, Cat D or Rab5 available.
- 1 AD did not have traf6, LilrB2, pmTORs2448, pmTORs2481, mTOR or p62 available.
**
The amyloid levels in the table are log-transformed.
SD, Standard deviation; Aβ40, β-amyloid1-40; Aβ42, β-amyloid1-42; CatD, cathepsin D; NCI, no cognitive impairment, MCI; mild cognitive impairment; AD, Alzheimer disease; mTOR, mammalian target of rapamycin; pMTOR, phosphorylated mTOR; LilrB2, leukocyte immunoglobulin-like receptor B2.